Surma StanisŁaw, Romańczyk Monika, Łabuzek Krzysztof
Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland.
Specialist Medical Practice in Jaworzno, Poland.
Pol Merkur Lekarski. 2020 Jun 17;48(285):195-198.
Arterial hypertension is the most common comorbid disease in patients who died as a result of SARS-Cov-2 infection. Numerous observational studies indicate a relationship between arterial hypertension and its treatment and SARS-Cov-2 coronavirus infection. It is known from experimental studies that SARS-Cov-2 enters the cells by interacting with the ACE2 enzyme, while it is not known whether ACE2 is the only factor that allows the virus to enter the cell. There is no clear evidence of a link between the use of medications such as ACE and ARB and an increased risk of SARS-Cov-2 infection. It has been shown that the use of recombinant ACE2 can be potentially beneficial in COVID-19 therapy by limiting the entry of the virus into the cell. Blood glucose as well as lipid profile should be monitored during SARS-Cov-2 coronavirus infection. This article attempts to gather key information on arterial hypertension and COVID-19.
动脉高血压是因感染SARS-CoV-2而死亡的患者中最常见的合并症。大量观察性研究表明动脉高血压及其治疗与SARS-CoV-2冠状病毒感染之间存在关联。从实验研究中可知，SARS-CoV-2通过与ACE2酶相互作用进入细胞，但尚不清楚ACE2是否是病毒进入细胞的唯一因素。没有明确证据表明使用ACE和ARB等药物与SARS-CoV-2感染风险增加之间存在联系。研究表明，使用重组ACE2可能通过限制病毒进入细胞而对COVID-19治疗有潜在益处。在感染SARS-CoV-2冠状病毒期间应监测血糖和血脂水平。本文试图收集有关动脉高血压和COVID-19的关键信息。
